CA2257279A1 - Compositions et procedes retardant le processus du vieillissement et traitant les etats pathologiques relatifs a l'age - Google Patents

Compositions et procedes retardant le processus du vieillissement et traitant les etats pathologiques relatifs a l'age Download PDF

Info

Publication number
CA2257279A1
CA2257279A1 CA002257279A CA2257279A CA2257279A1 CA 2257279 A1 CA2257279 A1 CA 2257279A1 CA 002257279 A CA002257279 A CA 002257279A CA 2257279 A CA2257279 A CA 2257279A CA 2257279 A1 CA2257279 A1 CA 2257279A1
Authority
CA
Canada
Prior art keywords
magnetic field
serotonin
effective amount
pulsed magnetic
stimulant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002257279A
Other languages
English (en)
Inventor
Reuven Sandyk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to IL12740096A priority Critical patent/IL127400A0/xx
Priority to CA002257279A priority patent/CA2257279A1/fr
Priority to PCT/US1996/009440 priority patent/WO1997046244A1/fr
Priority to AU59898/96A priority patent/AU5989896A/en
Publication of CA2257279A1 publication Critical patent/CA2257279A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N2/00—Magnetotherapy
    • A61N2/02—Magnetotherapy using magnetic fields produced by coils, including single turn loops or electromagnets
CA002257279A 1996-06-06 1996-06-06 Compositions et procedes retardant le processus du vieillissement et traitant les etats pathologiques relatifs a l'age Abandoned CA2257279A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
IL12740096A IL127400A0 (en) 1996-06-06 1996-06-06 Compositions and method which retard the aging process and which improve age-related disease conditions
CA002257279A CA2257279A1 (fr) 1996-06-06 1996-06-06 Compositions et procedes retardant le processus du vieillissement et traitant les etats pathologiques relatifs a l'age
PCT/US1996/009440 WO1997046244A1 (fr) 1996-06-06 1996-06-06 Compositions et procedes retardant le processus du vieillissement et traitant les etats pathologiques relatifs a l'age
AU59898/96A AU5989896A (en) 1996-06-06 1996-06-06 Compositions and method which retard the aging process and which improve age-related disease conditions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA002257279A CA2257279A1 (fr) 1996-06-06 1996-06-06 Compositions et procedes retardant le processus du vieillissement et traitant les etats pathologiques relatifs a l'age
PCT/US1996/009440 WO1997046244A1 (fr) 1996-06-06 1996-06-06 Compositions et procedes retardant le processus du vieillissement et traitant les etats pathologiques relatifs a l'age

Publications (1)

Publication Number Publication Date
CA2257279A1 true CA2257279A1 (fr) 1997-12-11

Family

ID=25680688

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002257279A Abandoned CA2257279A1 (fr) 1996-06-06 1996-06-06 Compositions et procedes retardant le processus du vieillissement et traitant les etats pathologiques relatifs a l'age

Country Status (3)

Country Link
CA (1) CA2257279A1 (fr)
IL (1) IL127400A0 (fr)
WO (1) WO1997046244A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE476188T1 (de) * 2002-05-14 2010-08-15 Nipro Corp Medikament zur prävention und behandlung von familiärer amyloid polyneuropathie
US7186209B2 (en) 2003-10-09 2007-03-06 Jacobson Jerry I Cardioelectromagnetic treatment
US9724534B2 (en) 2008-08-25 2017-08-08 Applied Magnetics, Llc Systems and methods for providing a magnetic resonance treatment to a subject
WO2010006175A1 (fr) 2008-07-10 2010-01-14 Applied Magnetics, Llc Pilotes de génération de signal extrêmement précis et à bas niveau, systèmes et procédés d'utilisation
DE102009043728A1 (de) 2009-10-01 2011-04-07 Albert Hesse Verfahren zur Behandlung von Übergewicht

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5157031A (en) * 1983-08-02 1992-10-20 Research Corporation Technologies, Inc. Method for prophylaxis of obesity
US4871550A (en) * 1986-09-05 1989-10-03 Millman Phillip L Nutrient composition for athletes and method of making and using the same
US5470846A (en) * 1994-01-14 1995-11-28 Sandyk; Reuven Treatment of neurological and mental disorders

Also Published As

Publication number Publication date
WO1997046244A1 (fr) 1997-12-11
IL127400A0 (en) 1999-10-28

Similar Documents

Publication Publication Date Title
US5691325A (en) Method for ameliorating age-related disease conditions
US5470846A (en) Treatment of neurological and mental disorders
US5691324A (en) Methods useful for the treatment of neurological and mental disorders related to deficient serotonin neurotransmission and impaired pineal melatonin functions
Hoheisel et al. Functional reorganization in the rat dorsal horn during an experimental myositis
Sandyk Clinical case report: Successful treatment of multiple sclerosis with magnetic fields
Janowsky et al. Testosterone influences spatial cognition in older men.
Seltzer et al. Alteration of human pain thresholds by nutritional manipulation and L-tryptophan supplementation
Bartsch et al. The pineal gland and cancer: neuroimmunoendocrine mechanisms in malignancy
Tsubokawa et al. Thalamic relay nucleus stimulation for relief of intractable pain. Clinical results and β-endorphin immunoreactivity in the cerebrospinal fluid
Mickle et al. Antinociceptive effects of melatonin in a rat model of post-inflammatory visceral hyperalgesia: a centrally mediated process
JP2003527320A (ja) 注意不足機能亢進障害および多発性硬化症疲労の治療のためのモダフィニルを含む組成物
Li et al. 5-Hydroxytryptamine: a modulator of food composition but not quantity?
Cocks et al. Effects of neuronal polypeptides on intestinal smooth muscle; a comparison with non-adrenergic, non-cholinergic nerve stimulation and ATP
Gersh et al. Applications of transcutaneous electrical nerve stimulation in the management of patients with pain: state-of-the-art update
Schoenenberger Characterization, properties and multivariate functions of delta-sleep-inducing peptide (DSIP)
EP0388226B1 (fr) Moyen de traitement de la démence sénile, des troubles de la mémoire et états comparables
JP5501395B2 (ja) Ｎ−メチル−ｄ−アスパレート受容体のｎｒ２−ｂサブユニットが関与している症候群または病態と闘うための治療薬
EP2644198A1 (fr) Utilisation de l'albiflorine ou d'un métabolite de celle-ci dans la lutte contre l'anxiété et pour l'amélioration de troubles du sommeil
Irintchev et al. Glycomimetic improves recovery after femoral injury in a non-human primate
CN115835901A (zh) 用于治疗癌症相关恶病质的组合物和方法
CA2257279A1 (fr) Compositions et procedes retardant le processus du vieillissement et traitant les etats pathologiques relatifs a l'age
Mayron Ecological factors in learning disabilities
EA001159B1 (ru) Композиции, содержащие фосфатидные кислоты
Leibowitz et al. Neurochemical controls of appetite
Takazawa et al. Potent and long-lasting anticonvulsant effects of 1-naphthylacetyl spermine, an analogue of Joro spider toxin, against amygdaloid kindled seizures in rats

Legal Events

Date Code Title Description
FZDE Discontinued